Welcome to Anagrammer Crossword Genius! Keep reading below to see if sirolimus is an answer to any crossword puzzle or word game (Scrabble, Words With Friends etc). Scroll down to see all the info we have compiled on sirolimus.
sirolimus
Searching in Crosswords ...
The answer SIROLIMUS has 0 possible clue(s) in existing crosswords.
Searching in Word Games ...
The word SIROLIMUS is NOT valid in any word game. (Sorry, you cannot play SIROLIMUS in Scrabble, Words With Friends etc)
There are 9 letters in SIROLIMUS ( I1L1M3O1R1S1U1 )
To search all scrabble anagrams of SIROLIMUS, to go: SIROLIMUS?
Rearrange the letters in SIROLIMUS and see some winning combinations
5 letters out of SIROLIMUS
4 letters out of SIROLIMUS
3 letters out of SIROLIMUS
Searching in Dictionaries ...
Definitions of sirolimus in various dictionaries:
SIROLIMUS - Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection and to treat a ...
Word Research / Anagrams and more ...
Keep reading for additional results and analysis below.
Sirolimus description |
---|
Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection and to treat a rare lung disease called lymphangioleiomyomatosis. It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2) through mTOR inhibition.It is produced by the bacterium Streptomyces hygroscopicus and was isolated for the first time in 1972 by Surendra Nath Sehgal and colleagues from samples of Streptomyces hygroscopicus found on Easter Island. The compound was originally named rapamycin after the native name of the island, Rapa Nui. Sirolimus was initially developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties due to its ability to inhibit mTOR. It was approved by the US Food and Drug Administration in September 1999 and is marketed under the trade name Rapamune by Pfizer (formerly by Wyeth). |